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Abstract
Introduction: Activated Protein C (APC), an endogenous anticoagulant, improves tissue microperfusion and 
endothelial cell survival in systemic inflammatory states such as sepsis, but intravenous administration may cause 
severe bleeding. We have thus addressed the role of APC delivered locally by inhalation in preventing acute lung injury 
from alveolar overdistention and the subsequent ventilator-induced lung injury (VILI). We also assessed the effects of 
APC on the activation status of Extracellular- Regulated Kinase 1/2 (ERK) pathway, which has been shown to be 
involved in regulating pulmonary responses to mechanical stretch.
Methods: Inhaled APC (12.5 μg drotrecogin-α × 4 doses) or saline was given to tracheotomized C57/Bl6 mice starting 
20 min prior to initiation of injurious mechanical ventilation with tidal volume 25 mL/Kg for 4 hours and then hourly 
thereafter; control groups receiving inhaled saline were ventilated with 8 mL/Kg for 30 min or 4 hr. We measured lung 
function (respiratory system elastance H), arterial blood gases, surrogates of vascular leak (broncho-alveolar lavage 
(BAL) total protein and angiotensin-converting enzyme (ACE)-activity), and parameters of inflammation (BAL 
neutrophils and lung tissue myeloperoxidase (MPO) activity). Morphological alterations induced by mechanical 
ventilation were examined in hematoxylin-eosin lung tissue sections. The activation status of ERK was probed in lung 
tissue homogenates by immunoblotting and in paraffin sections by immunohistochemistry. The effect of APC on ERK 
signaling downstream of the thrombin receptor was tested on A549 human lung epithelial cells by immunoblotting. 
Statistical analyses were performed using ANOVA with appropriate post-hoc testing.
Results: In mice subjected to VILI without APC, we observed hypoxemia, increased respiratory system elastance and 
inflammation, assessed by BAL neutrophil counts and tissue MPO activity. BAL total protein levels and ACE activity were 
also elevated by VILI, indicating compromise of the alveolo-capillary barrier. In addition to preserving lung function, 
inhaled APC prevented endothelial barrier disruption and attenuated hypoxemia and the inflammatory response. 
Mechanistically, we found a strong activation of ERK in lung tissues by VILI, which was prevented by APC, suggestive of 
pathogenetic involvement of the Mitogen-Activated Kinase pathway. In cultured human lung epithelial cells 
challenged by thrombin, APC abrogated the activation of ERK and its downstream effector, cytosolic Phospholipase A2.
Conclusions: Topical application of APC by inhalation may effectively reduce lung injury induced by mechanical 
ventilation in mice.
Introduction
Acute lung injury (ALI), a form of pulmonary edema due
to increased microvascular permeability, is a major cause
of respiratory failure, morbidity and mortality in the ICU.
Commonly seen as a complication of sepsis, ALI can be
exacerbated by the use of mechanical ventilation, which is
the main life-support modality for these patients [1,2].
Ov e r d i s t e n t i o n  o f  d i s e a s e d  a l v e o l i  b y  p o s i t i v e  p r e s s u r e
promotes inflammation and further disrupts the alveolo-
capillary membrane [3-5]. This occurs by mechanisms
including capillary stress failure, plasma membrane
microrupture and lung cell death [6-9]. In addition,
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stretch can elicit biochemical signaling events through
activation of mechanical sensors present in lung cells,
including stretch-activated ion channels, the cytoskele-
ton, and integrins [5]. The mitogen-activated protein
kinase (MAPK) enzyme family transduces many of these
signals and mediates cellular responses to stretch. The
importance of these enzymes is underscored by the bene-
ficial effects observed by MAPK antagonism in various
models of ventilator-induced lung injury (VILI) [10-12].
Limiting tidal volume (Vt) can reduce mortality by pre-
venting ventilator injury but this complication may still
occur with substantial frequency [4,13-16]. Therefore,
additional therapeutic options are clearly needed and
intervening in the underlying biochemical pathways with
drugs could be a rational approach.
A recent development in the management of sepsis has
been the launch of activated protein C (APC), an endoge-
nous anticoagulant with additional cytoprotective,
immunomodulatory and endothelial barrier-enhancing
properties, which constitute important defence mecha-
nisms in sepsis [17-21]. These attributes make APC an
attractive consideration for clinical conditions associated
with increased microvascular permeability in general,
including ALI, irrespective of the presence of sepsis. In
fact, as recently reported, intravenous APC could be use-
ful at reversing experimental ALI caused by mechanical
ventilation [22].
In clinical studies, low plasma levels of protein C have
been linked to increased risk of death in patients with
ALI [23] and APC supplementation improved tissue per-
fusion in septic patients [24]. Moreover, infusion of
recombinant human APC has been shown to reduce
mortality of patients with severe sepsis and at high risk of
death [25-27] presumably by reversing the sepsis-associ-
ated proinflammatory and procoagulant state and thus
preserving organ function. However, no benefit could be
demonstrated in pediatric patients or in adults with less
severe sepsis [28] or non-septic ALI [29]. These results,
coupled with the drug's potential to cause bleeding and
its substantial cost, have recently dampened the enthusi-
asm of the critical care community toward this agent and
more studies have been ordered by international authori-
ties.
In this context, exploring alternate dosing schemes and
routes of administration may be helpful in elucidating
how to optimally use the agent. The issue of bleeding
could be addressed in the lung by local delivery, which
would allow build-up of high concentrations of APC in
the alveolar space, thus maximizing local cyto-protec-
tion, while minimizing the risk of systemic anticoagula-
tion-related side effects. We and others have previously
demonstrated the feasibility and efficacy of this approach
in various experimental systems [30-32]. In this work we
tested the utility of inhaled APC in a mouse model of ALI
induced by high tidal volume (HVt) positive-pressure
mechanical ventilation. As VILI arises from excessive
stretch primarily of pulmonary epithelial and endothelial
c e l l s ,  w e  h y p o t h e s i z e d  t h a t  a i r s p a c e  d e l i v e r y  o f  A P C
would protect mouse lungs against this type of insult by
targeting the affected cell populations directly. In this
respect we measured lung function, indices of microvas-
cular permeability and inflammation in order to quantify
the extent of lung injury and the effect of APC. We then
specifically explored the activation status of the MAPK
pathway in order to gain mechanistic insight into the
APC action in our model. We found that inhaled APC
was associated with improved lung function and oxygen-
ation, in addition to a reduction in lung inflammation and
vascular leak. Extracellular-regulated kinase 1/2 (ERK)
activation was attenuated by APC in lung homogenates,
in addition to A549 human lung epithelial cells chal-
lenged with thrombin.
Materials and methods
Mice
Ten to fourteen week-old C57/Black6 male mice, with a
mean ± standard deviation weight at the time of experi-
ments of 22.7 ± 1.5 g, were purchased from the Biomedi-
cal Sciences Research Center 'Alexander Fleming', Vari,
Greece. Mice were housed at 20 to 22°C, 55 ± 5% humid-
ity, and a 12 hour light-dark cycle; food and water were
given ad libitum. All experimentation was approved by
an internal Institutional Review Board, as well as by the
veterinary service of the local governmental prefecture.
Reagents
All reagents were purchased from Sigma (Ilioupoli,
Greece) or as specified.
Experimental VILI
Outline of experimental protocol
Anesthesia was induced in mice by intraperitoneal injec-
tion of 80 mg/Kg sodium pentothal. A maintenance dose
of one-third of the induction dose was required in most
animals. Mice were intubated with 21 G unbeveled steel
cannula via tracheostomy and connected to a Flexivent
rodent ventilator (Scireq, Ontario, Canada) using ambi-
ent air to provide positive-pressure ventilation with low
tidal volume (LVt) settings: Vt 8 mL/Kg, and respiratory
rate 150 breaths per min (bpm). Positive end-expiratory
pressure (PEEP) was applied with water trap connected to
the expiratory limb of the ventilator circuit. After a run-in
period of five minutes, APC or normal saline (NS) were
administered via nebulization as described below. Twenty
minutes after treatment administration, the measure-
ment procedure was initiated. At the beginning, two deep
inflations were delivered by the ventilator to standardize
volume history. This was followed by a six-minute inter-Maniatis et al. Critical Care 2010, 14:R70
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val of LVt ventilation, at the end of which lung mechanics
(total pulmonary input impedance Zp by forced oscilla-
tion technique) were measured by applying an eight sec-
ond oscillatory flow waveform at the airway opening. The
measurement procedure was repeated twice at 30-second
intervals. Immediately after lung mechanics assessment,
ventilator settings were adjusted depending on the exper-
imental group to which each animal was assigned. The
measurement procedure was repeated hourly as
described and was followed by administration of the
treatment or sacrifice of the animal at the end of the pro-
tocol. Succinylcholine 8 mg/Kg intraperitoneally was
injected hourly prior to obtaining lung function measure-
ments and after ensuring adequate levels of anesthesia by
paw pinch. For a schematic representation of the experi-
mental protocol and measurement procedure please refer
to see Figure S1 in Additional file 1.
Sample collection
At the end of the ventilation protocol, an arterial blood
sample was obtained from the left ventricle and the
abdominal large vessels were severed to allow exsan-
guination. Bronchoalveolar lavage (BAL) was obtained by
injecting and slowly withdrawing three aliquots of 1 mL
of PBS each. BAL fluid was separated from cellular com-
ponents by centrifugation at 800 g for five minutes at 4°C
and stored at -80°C. The blood was flushed out of the
lungs by injecting 10 mL of PBS in the right ventricle. The
right lung was snap-frozen in liquid nitrogen. The left
lung was placed in 10% formalin for 24 hours and subse-
quently in 70% ethanol until processing.
Experimental groups and VILI protocol
To induce VILI, mice were ventilated with HVt ventila-
tion of Vt 25 mL/Kg, respiratory rate 50 bpm and PEEP of
2 cmH2O for four hours. Mice subjected to HVt received
either 12.5 μg of recombinant human APC (drotrecogin
α; Pharmaserve-Lilly, Kifisia, Greece) dissolved in 30 μL
NS (HVt-APC group, n = 6), or 30 μL NS without APC
(HVt-NS group n = 6). Treatments were administered as
a bolus inhalation over five minutes via an Aeroneb nebu-
lizer specially designed for use in rodents (Scireq,
Ontario, Canada). In addition to the animals undergoing
VILI, two control groups of LVt  were included in this
study: in the first control group, (LVt-30 min, n = 6) mice
were ventilated with LVt  settings for 30 minutes. Mea-
surements in this group of animals represent values of
uninjured lungs. A second control group (LVt-4 hr, n = 6)
was ventilated with LVt settings for four hours, to allow
assessment of the HVt effect during this time period (i.e.
four hours) on basic parameters of lung function and
inflammation (elastance, blood gases, neutrophil counts
in BAL, total BAL protein levels, histology). In both LVt
groups a PEEP of 2 cmH2O was applied
Dose-response testing
Mice were ventilated with LVt as described. After a three-
minute run-in period and two deep inflations, increasing
doses of APC were administered by nebulization. A
three-second forced-oscillation perturbation was applied
to the airway every 10 seconds to determine lung func-
tional properties in response to APC. Every five minutes
the dose of APC was increased as shown in Figure 1, up
to a maximum dose of 100 μg.
Lung mechanics
Total respiratory system impedance Zp was measured
throughout a range of frequencies applied to the airway
opening during an eight-second perturbation [33]. To
obtain Zp, an oscillatory wave consisting of a range of
mutually prime frequencies was applied to the airway
opening during an eight-second perturbation [33]. Using
a mathematical model, Zp can be compartmentalized
into elastance H, resistance RN, viscous energy dissipation
G and inertance I [34]. For dose-response experiments a
three-second perturbation was applied. Only values with
the highest accuracy (coefficient of determination of 0.9
or greater) were included. The yield of usable measure-
ments in this study was more than 90%.
Figure 1 Dose-response curve of airway resistance (RN) and lung 
tissue elastance (H) to inhaled APC. Increasing doses ranging be-
tween 12.5 and 100 μg of inhaled activated protein C (APC) were ad-
ministered to three mice and lung function was measured every 10 
seconds. Airway resistance (RN, top) and lung elastance (H, bottom) 
started to increase at 25 μg. We therefore used 12.5 μg for the remain-
ing experiments. The symbols (square, diamond and triangle) repre-
sent measurements obtained from each of the three mice used in this 
experiment.
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Arterial blood gases
Partial pressure of arterial oxygen and carbon dioxide and
pH were measured using a blood gas analyzer (Radiome-
ter Kopenhagen, Kopenhagen, Denmark)
BAL total protein
Total protein concentration in the BAL was determined
with the Bio-Rad Dc Protein Assay kit (Bio-Rad Laborato-
ries, Hercules, CA, USA) according to the manufacturer's
instructions.
Myeloperoxidase assay
Excised lungs were snap-frozen in liquid nitrogen,
weighed and stored at -80°C. Lungs were homogenized
for 30 seconds in 1 mL homogenization buffer (50 mM
potassium phosphate pH 6.0, 0.5% hexadecyltrimeth-
ylammonium bromide, 5 mM EDTA) on ice. The homo-
genate was incubated at 60°C for two hours, centrifuged
at 14,000× g for 30 minutes at 4°C and the supernatants
were transferred into clean tubes. Samples of 3.75 μL
were added to 296 μL of assay buffer (0.0005% H2O2,
0.167 mg/mL o-dianisidine hydrochloride in 100 mM
potassium phosphate buffer) in 96-well plate in tripli-
cates. Absorption was measured with a spectrophotome-
ter (Tecan GENios, Männedorf, Switzerland) every 10
seconds for one minute. Thus obtained absorbance values
increase linearly with time. Myeloperoxidase (MPO)
activity A was expressed as change of optical density
(ΔOD)/min/g of lung tissue.
Angiotensin-converting enzyme activity
Angiotensin-converting enzyme (ACE) activity was
determined in BAL fluid using fluorometric assay. Sam-
ples of 20 μL of BAL fluid were incubated with 200 μL of
5 mM Hippuryl-His-Leu for 15 hours at 37°C. The reac-
tion was stopped with 20 μL 2.8 N NaOH and 20 μL o-
pthaldialdehyde (20 mg/ml in methanol) was then added
for 10 minutes at room temperature to tag His-Leu,
which is released following cleavage of Hippuryl-His-Leu
by ACE. Finally, 20 μL of 3N HCL were added to termi-
nate this reaction. Fluoresence was measured at an exci-
tation wavelength of 360 nm and emission wavelength of
465 nm (Tecan GENios, Männedorf, Switzerland). To
determine ACE activity from fluorescence measure-
ments, we used a standard curve of His-Leu.
Western blot for ERK
Lung tissue samples were homogenized for 30 seconds in
ice-cold lysis buffer (Radio-Immuno-Precipitation-Assay
Buffer, 150 mM NaCl, 1% NP-40, 0.5% deoxycholic acid,
0.1% Sodium Dodecyl-Sulfate, 50 mM Tris pH = 8) Sigma
(Ilioupoli, Greece) and centrifuged to separate insoluble
components. Laemmli buffer was added to supernatants
and samples were boiled for five minutes and subjected to
electrophoresis as described [35]. Briefly, proteins were
separated on a 10% SDS-PAGE and electrotransferred to
polyvinylidene fluoride membranes. Membranes were
blocked in buffer containing 20 mM Tris-HCl, pH 7.4,
137 mM NaCl and 0.1% Tween 20 (TBST), in addition to
5% non-fat dry milk, for one hour at room temperature.
The membranes were then incubated overnight at 4°C
with primary antibody (anti-phospho-Thr202/Tyr204
ERK, anti-ERK, anti-phospho Ser 505 cPLA2 or cPLA2
antibody, all Cell Signaling, Beverly, MA, USA). After
washing in TBST, blots were incubated for one hour at
room temperature with the appropriate horseradish per-
oxidase-conjugated secondary antibody. Protein bands
were visualized using the Supersignal west pico chemilu-
minescent substrate (Pierce Biotechnology, Rockford, IL,
USA). To ensure equal loading, membranes were probed
with anti-tubulin or anti-actin antibody. Densitometric
analysis of the films was performed with the Image J anal-
ysis software (National Institutes of Health, Bethesda,
MD, USA).
Histology and immunohistochemistry for ERK
Sections of formalin-fixed, paraffin-embedded tissue (5
μm) were deparaffinized in xylene and rehydrated in alco-
hol. H&E staining was performed according to standard
protocols. To perform antigen retrieval for immunohis-
tochemistry, slides were boiled in 0.01 mol/L sodium cit-
rate buffer (pH 6.0) for 15 minutes in a microwave oven.
Sections were incubated with monoclonal rabbit anti-
phospho-Thr202/Tyr204 ERK (1:500) overnight and anti-
body binding was detected using Vectastain Elite ABC
Kit (Vector Laboratories, Burlingame, CA, USA). Visual-
ization was performed with 3,3-diaminobenzidine (Vec-
tor Laboratories, Burlingame, CA, USA) as chromogen.
S l i d e s  w e r e  c o u n t e r s t a i n e d  w i t h  H & E ,  d e h y d r a t e d  a n d
mounted. Images were acquired with a camera mounted
on an Olympus (BX50) microscope (Fotomatic AE, Ath-
ens, Greece using 40 × objective. Histological scoring was
undertaken by an observer blinded to group allocation, as
described [6].
Cell culture
A549 cells purchased from American Type Culture Col-
lection (Manassas, VA, USA) were cultured in F-12K
Kaighn's medium (Gibco, Carlsbad, CA, USA) containing
10% FBS, 2 mM glutamine and 10% antibiotics. A549 cell
were seeded in six-well plates and grown at 37°C, in 5%
carbon dioxide, in a complete medium. Confluent cul-
tures were incubated in serum-free medium for 24 hours.
Quiescent cultures were pretreated or not with APC (10
μg/mL) for one hour and exposed to thrombin (0.5 U/mL;
Enzyme Research Labs, Swansea, UK) for 15 minutes. In
certain experiments, cultures were incubated with the
Mitogen-Activated-Protein-Kinase-Kinase (MEK) inhibi-Maniatis et al. Critical Care 2010, 14:R70
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tor, UO126 (Merck KGaA, Darmstadt, Germany) dosed
at 25 μM for one hour.
Statistical analysis
Data are presented as mean ± standard deviation. Groups
were compared using parametric or non-parametric one-
way analysis of variance, as appropriate. For post-hoc
comparisons, the LVt-30 min group was used as the refer-
ence group and all others were compared with this one
using the Dunnett's test, with the exception of lung
mechanics (Figure 2), where comparisons were made
over time against the LVt-4 hr group. Groups that statisti-
cally differ from the LVt-30 min group are marked by an
asterisk. The rationale for comparing against the LVt-30
min group was that this group represents the uninjured
state of the lung. All P values are two-sided; P values less
than 0.05 were considered statistically significant.
Results
Optimal inhaled APC dose
Á dose-response curve of inhaled APC was prepared by
administering increasing concentrations of the drug to
three mice and measuring lung elastance H and airway
resistance RN every 10 seconds for 30 minutes (Figure 1).
W e  f o u n d  t h a t  a t  a  d o s e  o f  2 5  μ g  t h e r e  w a s  a  s l i g h t
increase in H whereas RN increased at the 75 μg dose. We
therefore used hourly inhalations of 12.5 μg/30 μL for our
experiments, because this seemed to be well tolerated
without changes in lung function.
Figure 2 Effect of inhaled APC on airway resistance (RN) and lung elastance (H) in mechanically ventilated mice. Airway resistance and lung 
tissue elastance were measured hourly in mice subjected to injurious ventilation (high tidal volume (HVt)). Airway resistance (top) in mice of the LVt-
4 hr group was constant throughout the experiment, whereas it trended downwards in mice receiving HVt. From two hours and onward, elastance 
(bottom) was significantly lower in mice treated with activated protein C (APC) compared with those receiving saline (NS). Mice ventilated with pro-
tective (low tidal volume (LVt)) ventilation served as reference (data expressed as mean ± standard deviation; * denotes P < 0.05; one-way analysis of 
variance for each time-point with post-hoc analysis by Dunnett's test).
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Inhaled APC prevents deterioration of lung function in 
response to alveolar distention
W e  o b t a i n e d  s e r i a l  m e a s u r e m e n t s  o f  l u n g  f u n c t i o n  i n
mice treated with inhaled APC or NS using the forced
oscillation technique, an invasive but sensitive method to
assess lung mechanical properties in intubated rodents
(Figure 2). Baseline values of H did not differ between
groups. However, after two hours of injurious ventilation
and onward, H was significantly higher in mice receiving
NS than in mice treated with inhaled APC or mice venti-
lated with LVt. At the end of four hours, H was 46.0 ± 8.6
cmH2O/mL in the HVt-NS group (i.e. a 36.4% increase
from baseline) and 36.2 ± 2.7 cmH2O/mL in the HVt-
APC group (P < 0.05), corresponding to a 16% increase
from baseline. In mice ventilated with LVt, H did not
increase significantly, regardless of whether NS or APC
was administered (Figure 2) [see Figure S2 in Additional
File 1].
Inhaled APC preserves pulmonary microstructural integrity 
in VILI
Examination of H&E-stained lung tissue sections (Figure
3) was performed in order to verify microanatomical fea-
tures of lung injury imposed by ventilator stretch, to
assess how they are affected by APC and to determine if
APC administration was associated with alveolar hemor-
rhage. Both LVt groups showed normal histology (Figure
3). In the HVt-NS group, we found alveolar septal thick-
ening, indicative of edema formation. We also found
mononuclear cell infiltration of the alveolar walls, intraal-
veolar erythrocytes and hyaline membranes. These alter-
ations were markedly attenuated in the HVt-APC group.
No evidence of increased intraalveolar bleeding was seen
in APC-treated lungs treated with HVt or LVt (Figure 3)
[see Figure S2 in Additional file 1].
Inhaled APC attenuates increased permeability response to 
VILI
To assess the integrity of the alveolo-capillary membrane,
we determined total protein concentration in BAL speci-
mens from mice undergoing control and injurious venti-
lation (Figure 4). Total protein increased roughly fourfold
in the HVt-NS group compared with LVt-30 min, indicat-
ing lung injury due to increased microvascular permea-
bility imposed by excessive Vt  ventilation. In contrast,
APC administration prevented the increase in permeabil-
ity, indicating protection of microvascular barrier integ-
rity by APC.
APC prevents hypoxemia from ventilator injury
As ALI is expected to induce hypoxemia due to ventila-
tion-perfusion mismatching and intrapulmonary shunt-
ing, we obtained arterial blood gases at the end of each
experimental protocol from our mice as markers of the
above physiological alterations (Figure 5). We observed
marked hypoxemia in mice subjected to HVt ventilation
compared with both LVt  groups (P < 0.05; Figure 5). In
contrast, HVt-APC mice did not differ from LVt animals
in blood oxygen partial pressure. In addition, we found
non-significant trends towards more acidosis and hyper-
carbia in HVt-NS mice compared with LVt and HVt-APC
mice (Figure 5).
Decreased ACE activity in BAL of APC-treated mice
ACE is expressed on the surface of pulmonary microvas-
cular endothelial cells and is shed in the bloodstream fol-
lowing enzymatic cleavage. In ALI, membrane-bound
ACE declines and soluble ACE increases [36,37]. Thus, in
the presence of lung microvascular barrier disruption,
ACE may diffuse in the alveolar space. We found low lev-
els of enzymatic ACE activity in the BAL of LVt-30 min
mice (1.5 ± 0.3 mU/mL) but an almost twofold increase in
the HVt-NS group (2.8 ± 0.7 mU/mL; P < 0.05; Figure 4).
However, APC attenuated the rise in ACE activity
induced by HVt, indicating a reduction in the degree of
lung injury.
APC-treated mice show reduced neutrophilic inflammation 
in airspace
As ALI, including ventilator-induced trauma, is accompa-
nied by pulmonary inflammation, we ascertained the
d e g r e e  o f  t h e  n e u t r o p h i l i c  r e s po n s e  t o  V I L I  i n  t h e  a i r
space by counting the numbers of neutrophils present in
the BAL. These were markedly increased in HVt-NS mice
compared with both LVt  groups (P  < 0.05; Figure 6).
Administration of APC reduced BAL neutrophils by
roughly 50%.
Reduced lung tissue neutrophil infiltration by APC
We used MPO activity as a marker of lung tissue neutro-
phil infiltration (Figure 6). MPO activity increased in
HVt-NS mice compared with LVt-30 min but to a lesser
extend in the HVt-APC group (P < 0.05; Figure 6).
Alveolar distention activates the mitogen-activated protein 
kinase pathway
The MAPK pathway, of which ERK is an important mem-
ber, is crucial to the generation of the inflammatory
response in resident lung cells. To assess the time course
of ERK activation, we ventilated mice with HVt or LVt for
various time points. Using immunoblotting in whole lung
extract, we observed that this pathway is triggered early
in the course of our experiment, already after 30 minutes
of HVt, and increases further after 60 minutes of HVt
(Figure 7).
ERK activation is inhibited by APC
We next examined the effect of APC administration on
activation of the ERK pathway. Therefore, we determinedManiatis et al. Critical Care 2010, 14:R70
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the phosphorylation status of ERK by immunoblotting in
lung tissue specimens from HVt-APC and HVt-NS mice
(Figure 8). At the end of four hours, levels of activated
ERK were higher in the HVt-NS group than in the HVt-
APC group (Figure 8). Total ERK expression did not differ
between the two groups (data not shown). In contrast to
ERK, activity of c-Jun NH2-terminal kinase (JNK),
another member of the MAPK family, was no different
between LVt-30 min mice and any of the two HVt groups
(not shown). To determine the location of activated ERK
in the lung parenchyma we performed immunohis-
tochemical staining in lung tissue sections (Figure 8). We
found that phosphorylated ERK localized primarily in
epithelial and endothelial cells in the alveolar septa.
APC directly inhibits ERK activation in lung epithelial cells
To examine whether the observed effects of APC on ERK
activation are the result of direct or indirect inhibition,
we induced ERK activation in cultured human lung epi-
thelial cell line A549 by thrombin. As shown in Figure 8,
ERK activation by thrombin was induced within five min-
utes of thrombin addition to the medium and by APC
alone, but to a much lesser degree. Upon pre-incubation
with APC we observed that ERK phosphorylation by
thrombin was markedly attenuated. We also found that
phosphorylation of cytosolic phospholipase A2 (cPLA2)
was also activated by thrombin but the presence of APC
in the cell culture medium was associated with a reduc-
tion in phosphorylated cPLA2. We next examined the
Figure 3 VILI-induced microstructural alterations are attenuated by APC. Mouse lungs ventilated with LVt for 30 minutes (top left) or four hours 
(top right) showed normal microanatomy. Application of HVt (bottom left) induced histological changes comprising in alveolar septal widening, mono-
nuclear cell infiltration, alveolar hemorrhage and hyaline membrane formation. These changes were markedly attenuated by inhaled activated protein 
C (APC; bottom right). These observations were documented by semi-quantitative histological scoring (mean ± standard deviation; * denotes P < 0.05 
for comparison with LVt-30 min; one-way analysis of variance with post-hoc analysis by Dunnett's test). VILI, ventilator-induced lung injury. NS, normal 
saline.
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relation between ERK and cPLA2  in the presence of
thrombin. To this end, cells were stimulated with throm-
bin in the presence and absence of MEK1 and 2 inhibitor
U0126, a compound commonly used in ERK inhibition
studies. We found that addition of U0126 to the cell cul-
ture medium prevented ERK activation, as expected, in
addition to cPLA2 activation. (Figure 8).
Discussion
In this work, we present data to show that inhaled APC
ameliorates pulmonary edema and inflammation from
HVt positive pressure mechanical ventilation. In a recent
report, APC was shown to act via the endothelial protein
C receptor to attenuate vascular hyperpermeability in a
murine VILI model [22]; we now expand upon this obser-
vation by showing that APC via the inhalational route
may also be effective in this lesion by reducing ERK acti-
vation. These two complementary animal studies support
a role for APC in lung injury from excessive alveolar dis-
tention.
We and other investigators have used very large Vts to
cause lung injury in our studies. These ventilator settings
are never encountered in clinical practice, putting into
question the value of this experimental design. However,
in human acute respiratory distress syndrome (ARDS)
large portions of the lung may be collapsed due to edema
Figure 4 Inhaled APC preserves alveolo-capillary barrier function in VILI. BAL total protein concentration (top) increased in mice receiving saline 
(NS) and injurious ventilation (HVt) compared with a reference group of only briefly ventilated animals (LVt-30 min), indicating alveolo-capillary mem-
brane dysfunction. Activated protein C (APC) reduced protein leak in the airspace. Changes in broncho-alveolar lavage (BAL) angiotensin-converting 
enzyme activity (bottom) were also reversed by APC (data expressed as mean ± standard deviation; * denotes P < 0.05 for comparison with LVt-30 
min; One-way analysis of variance or Kruskal-Wallis test with post-hoc analysis by Dunnett's test). VILI, ventilator-induced lung injury.
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fluid, resulting in distention of the remaining paren-
chyma to a much greater extent than would be expected
from the LVts commonly used [2]. Hence, this experi-
mental approach may reproduce the conditions present
in these relatively functional lung areas. In addition, as no
other insult is present, this model allows the study of
alterations directly attributed to stretch.
Initial dose-response experiments revealed that the
highest bolus dose tolerated without changes in lung
function is 12.5 μg in this system. Higher doses increased
airway resistance and tissue elastance, possibly by induc-
ing bronchoconstriction. Increases in airway resistance
with APC have also been described with intravenous
injection in rats [38], although data in humans are lack-
ing. At the doses chosen the aforementioned phenomena
were not observed and no effects on other important out-
comes such as lung histology or mechanics could be doc-
umented by APC administration in lungs ventilated with
protective Vts [see Figure S2 in Additional file 1].
Physiological parameters, including edema and hypox-
emia, were used to quantify lung injury severity in our
model. Lung elastance, a measure of lung stiffness, rises
progressively in rodent VILI due to such alterations as
edema development and atelectasis due to surfactant dys-
function [6,39]. We have previously observed that this
parameter correlates well with markers of increased vas-
cular permeability in this model [6]. In our VILI experi-
ments, lung function in APC-treated mice was preserved
compared with mice receiving saline, which could be
interpreted as protection against pulmonary edema for-
mation by APC. Alternatively, APC may have facilitated
lung edema clearance, prevented surfactant depletion or
exerted an anti-inflammatory effect. In a similar respect,
APC abrogated the HVt-induced hypoxemia, implying
reductions in ventilation-perfusion mismatching and/or
intrapulmonary shunting by APC. Corresponding to its
effects on functional parameters, inhaled APC also pre-
vented histological alterations induced by HVt. Impor-
tantly, despite the high topical dose given, no hemorrhage
was observed in the lung or at any surgical site.
To assess microvascular and alveolar epithelial permea-
bility alterations by VILI we determined BAL total pro-
tein levels and ACE activity. BAL fluid total protein rose
in both HVt groups compared with mice ventilated with
Figure 5 Arterial blood gases. Arterial hypoxemia was less in mice treated with activated protein C (APC) compared with mice receiving saline (NS). 
There were also non-significant trends towards acidosis and hypercarbia in the HVt-NS group (data expressed as mean ± standard deviation; * denotes 
P < 0.05 for comparison with LVt-30 min; One-way analysis of variance with post-hoc analysis by Dunnett's test). PaCO2, partial pressureof arterial car-
bon dioxide; PaO2, partial pressureof arterial oxygen.
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LVt, indicating leakage of protein-rich fluid from the
intravascular to the alveolar compartment or induction of
cell death. As this rise was significantly greater in saline-
treated mice, APC treatment should have resulted in
preservation of alveolo-capillary membrane integrity or a
reduction in related cell death. To corroborate this obser-
vation using a defined plasma protein, we determined
ACE activity in the BAL. Application of HVts in our sys-
tem led to a rise in BAL ACE activity, a phenomenon
strongly attenuated by APC inhalation. Excess BAL ACE
in  HVt-NS mice likely originated from the plasma via
leaky microvessels. This finding provides further evi-
dence that APC preserves microvascular integrity in
VILI.
As neutrophilic inflammation may worsen lung dys-
function in VILI, we assessed the magnitude of the pul-
monary inflammatory response in our model and tested
whether exogenous APC is associated with a reduction in
lung neutrophil sequestration. APC administration led to
a decline in both airspace and tissue neutrophils, indicat-
ing that APC may have directly affected neutrophil
migration into the lung [20], and/or reduced parenchy-
mal cell death and chemotactic cytokine production.
In order to investigate the mechanism of action of APC
in our experimental model, we studied the impact of the
agent on ERK activation in lung tissue. ERK is a member
of the MAPK family, along with p38 and JNK. ERK is a
downstream effector of small GTPase RhoA, which is
activated in response to cyclic stretch and edemagenic
agents such as thrombin [40]. ERK may increase permea-
bility by promoting apoptosis, oxidant production and
activation of myosin-light chain kinase, which activates
molecular motor myosin to promote endothelial
cytoskeletal contraction and subsequent interendothelial
gap formation [12,41-43]. ERK is strongly activated in
VILI experiments and has been used as an injury marker
in VILI [44,45]. ERK inhibition by a small-molecule
inhibitor has been effective in rescuing a mouse model of
endotoxin-induced lung injury [46] and mixed models of
VILI and bleomycin or hyperoxia [12,47]. In agreement
with other studies [45], we found robust ERK activation
within 30 minutes of HVt application. Importantly, ERK
were still activated after four hours of HVt compared with
LVt, but significantly less in APC-treated lungs. ERKacti-
vation could be attributed directly to stretch and/or to the
effects of chemical mediators, including thrombin, on
alveolar cells. As APC is known to interfere with throm-
bin signalling pathways, particularly with regard to RhoA
activation, it is conceivable that the reduction in ERK
activity by APC reflects cellular, receptor-mediated
effects of APC. Alternatively, APC may have led to a
reduction in levels of inflammatory mediators, including
activated thrombin, as has been demonstrated in bleomy-
cin-induced fibrosis and asthma animal models of intra-
tracheal APC administration [30,32]. In contrast to ERK,
we found no difference in the activation status of JNK
between groups at four hours. This indicates that block-
ade of ERK, due to its sustained activation, could be a
useful strategy.
In in vitro studies we addressed the question whether
the effects of APC could be attributed directly to interfer-
ence with cell signaling processes as opposed to indirectly
reducing levels of inflammatory mediators. We stimu-
lated A549 human lung epithelial cells with thrombin, an
important inflammatory and pro-coagulant protease with
pathogenetic importance in experimental VILI [48] and
found marked ERK activation, which was attenuated by
APC, indicating that APC can directly alter thrombin sig-
naling. To date, most studies have focused on the actions
of APC on endothelial cells. Interestingly, however, pul-
monary epithelial cells seem to express APC and throm-
bin receptors [49,50], even though these proteases are
generally thought to be restricted to the endovascular
compartment. This is one of the first reports to show that
APC can modulate thrombin signaling in epithelial cells.
Activation of cPLA2, the rate-limiting enzyme in
arachidonic acid synthesis, has been implicated in the
pathogenesis of human ARDS and experimental VILI
[51,52] and thrombin is an important activator of cPLA2
downstream of ERK [53]. However, cPLA2 activation can
Figure 6 Airspace and lung tissue neutrophils. Broncho-alveolar la-
vage (BAL) neutrophil count (top) reflects airspace neutrophils. My-
eloperoxidase (MPO) activity (bottom) was used to detect lung tissue 
neutrophil infiltration. Both inflammatory markers were reduced by ac-
tivated protein C (APC), suggesting less lung injury (data expressed as 
mean ± standard deviation; * denotes P < 0.05 for comparison with LVt-
30 min; One-way analysis of variance or Kruskal-Wallis test with post-
hoc analysis by Dunnett's test).
16
A
L
*
8
12
i
l
s
/
 
L
 
B
A
4
8
n
e
u
t
r
o
p
h
i
0
n
LVt-30min HVt-NS LVt-4 hr HVt-APC
0 20
g
)
0.16
0.20
O
D
/
m
i
n
/
g
*
0.08
0.12
c
t
i
v
i
t
y
 
(
 
O
0
0.04
M
P
O
 
a
c
0
LVt-30min HVt-APC HVt-NSManiatis et al. Critical Care 2010, 14:R70
http://ccforum.com/content/14/2/R70
Page 11 of 14
be prevented by APC. Using pharmacologic ERK inhibi-
tion in A549 cells, we show that cPLA2 activation by
thrombin is contingent upon ERK. By preventing cPLA2
from accelerating arachidonic acid synthesis, APC may
be exerting some of its cytoprotective and anti-inflamma-
tory properties.
In summary, we found that topical application of APC
attenuated lung dysfunction, hypoxemia, protein perme-
ability and neutrophil infiltration in a mouse model of
ventilator injury. Our study adds another piece of experi-
mental evidence to show that APC, an endogenous anti-
coagulant and cytoprotective agent, could be effective in
non-septic inflammatory conditions. In fact, airway
application of this agent could be particularly useful to
reverse lung dysfunction from mechanical ventilation.
Contrary to sepsis, where patients are frequently seen at
an advanced stage in the disease process, the time of
onset of ventilator-associated lung trauma is well-
defined, namely when the patient with ALI is placed on
mechanical ventilation [54]. Thus, early administration of
protective agents could prevent the severe injury
incurred by artificial respiration to diseased lungs. Our
investigation provides impetus to consider translational
Figure 7 Activation of ERK by mechanical stretch and effect of APC. (a) Time-course of extracellular-regulated kinase 1/2 (ERK) activation by al-
veolar distention. Immunoblotting detection of phosphorylated (activated) ERK-1 (top band) and ERK-2 (bottom band) in reference to actin in mouse 
whole lung lysates following ventilation with tidal volume of 25 mL/Kg. ERK activation in lung tissue occurs rapidly, within 30 minutes and increases 
after 60 minutes of injurious ventilation. A representative blot of three experiments and band density analysis of cumulative results in reference to 
actin are presented. (b) Activated protein C (APC) reduces ERK activation in lung homogenate following ventilator-induced lung injury (VILI). Detection 
of activated ERK in mouse whole lung lysates by immunoblotting with antibodies binding specifically to phosphorylated ERK. ERK phosphorylation 
status after four hours of HVt ventilation remains higher in comparison with control mice. APC inhalation significantly diminishes ERK activation. A rep-
resentative blot and band density analysis of cumulative results in reference to tubulin are presented. (c) Immunohistochemical staining for activated 
ERK in lung tissue. Phospho-ERK-positive cells stain brown. VILI induces activation of ERK in alveolar cells, which can be prevented by APC. (data ex-
pressed as mean ± standard deviation; * denotes P < 0.05 for comparison with LVt-30 min; One-way analysis of variance with post-hoc analysis by Dun-
nett's test).
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approaches addressing the role of inhaled APC in this
clinical setting.
Conclusions
In this study, we addressed the effect of airway applica-
tion of inhaled APC as a prevention strategy for experi-
mental ventilator-induced lung injury. Ventilation of
healthy mouse lungs with excessive Vt  leads to lung
inflammation and edema. Inhaled APC attenuated
inflammation and maintained microvascular barrier
integrity, resulting in reduced lung functional impair-
ment and hypoxemia in response to alveolar stretch.
Associated biochemical events include a reduction in the
activation level of ERK, providing a potential mechanism
to explain the protective effects of APC administration.
Key messages
• Airway application of APC in high doses is well-tol-
erated by healthy mice
• Ventilation of uninjured mouse lungs with excessive
Vts induces lung alterations characterized by inflam-
mation and edema, resembling the lesions observed
in the ventilated lung regions in ARDS patients
• Inhaled APC can prevent lung dysfunction in this
model, and could be an interesting and relevant
approach to the management of ARDS, even in the
setting of coagulopathy
• ERK activation by alveolar stretch is reversed by
APC, indicating that this may be a central biochemi-
cal pathway that couples mechanical signals to cellu-
lar responses
Additional material
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Additional file 1 Schematic representation of experimental VILI pro-
tocol and effects of APC in mice receiving protective ventilation. Fig-
ure S1: Overview of experimental procedure for mechanical 
ventilation experiments. A: Temporal relation of mechanical ventilation, 
administration of nebulized treatments (Activated Protein C-APC or Normal 
Saline-NS) and lung mechanics measurements. B: Time-course of lung 
mechanics measurement procedure. Deep inflation: mechanical inflation to 
30 cmH2O. Prime-8: 8-sec forced oscillation meneuver to measure lung 
elastance H and airway resistance RN as described in 'Methods'. Figure S2: 
APC administration in mice receiving protective ventilation. We mea-
sured lung elastance H, airway resistance RN, BAL total protein and histolog-
ical lung injury score in mice receiving nebulized NS or APC and ventilated 
with protective ventilation (8 mL/kg) for 4 hr as shown in Figure 1E and 
described in 'Methods'. We found that protective ventilation and NS inhala-
tion induced no significant changes in lung mechanics as measured by the 
forced oscillation technique. In mice receiving APC we observed no signifi-
cant differences in lung mechanics, total BAL protein and histological injury 
compared to mice receiving NS (n = 3/group).
Figure 8 Effect of APC on thrombin signaling pathway in epithelial cells. (a) Activated protein C (APC) reverses thrombin-induced extracellular-
regulated kinase 1/2 (ERK) and cytosolic Phospholipase A2 (cPLA2) activation in A549 cells. Immunoblotting detection of activated (phosphorylated) 
ERK and cPLA2. A549 cells were incubated with serum-free medium, thrombin for 15 minutes, APC for 60 minutes or APC for 60 minutes followed by 
thrombin for 15 minutes. APC alone induced minimal ERK and cPLA2 activation. In contrast, thrombin addition was associated with increased activa-
tion of ERK and cPLA2, both of which were abrogated in the presence of APC (Representative of five experiments). (b) ERK phosphorylates cPLA2 down-
stream of the thrombin receptor. ERK activation was blocked by MEK inhibitor UO126 in A549 cells challenged with thrombin. Inhibition of ERK 
activation led to abrogated cPLA2 phosphorylation (representative of three experiments).
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